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Abstract 
Background: Epithelial mesenchymal transition (EMT) mediated by TGF‑β pays an important role in malignant 
tumor acquired abilities of migration and invasion. Our previous study showed that the extract of Stellera chamae-
jasme L. (ESC) was against proliferation of a variety of tumor cells, but there were no studies in the effects of ESC on 
EMT in tumor cells. In this study, TGF‑β was adopted to induce EMT in HepG2 cells and the influence of ESC on EMT 
was observed.
Methods: MTT assay was used to observe the cell viability. Wound healing assay and transwell assay were used to 
observe the migration and invasion activities. Western blot and immunofluorescence methods were used to observe 
the expression of proteins.
Results: We found that HepG2 cells induced by TGF‑β showed mesenchymal morphology, down‑regulation of 
epithelial marker E‑cadherin and up‑regulation of mesenchymal marker Vimentin, indicating that TGF‑β could medi‑
ate epithelial mesenchymal induction in HepG2 cells. ESC could reverse the mesenchymal morphology and regulate 
expressions of marker proteins in HepG2 induced by TGF‑β and significantly inhibit TGF‑β induced HepG2 cell migra‑
tion and invasion. We further found that ESC could also significantly depress Smad2 phosphorylation and nuclear 
translocation, and ESC had coordination with SB432542, a specific inhibitor of TβRI kinases.
Conclusions: These results suggested that the ESC could reverse epithelial mesenchymal transition induced by 
TGF‑β via inhibition Smad2 signaling pathway.
Keywords: Hepatocellular carcinoma, Stellera chamaejasme L., Transforming growth factor, Metastasis, Epithelial 
mesenchymal transition, Smad signaling pathway
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Background
In recent years, it is found that epithelial mesenchymal 
transition (EMT) is an important biological process for 
malignant tumor cells to obtain migratory and invasive 
ability and a key initiative step of invasion and metasta-
sis in tumors. EMT is characterized by up-regulation of 
mesenchymal markers (such as Vimentin) down-reg-
ulation of epithelial markers (such as E-cadherin) [1], 
and loss of cell–cell adhesion, which enables tumor 
cells to dissociate and migrate from the primary tumor 
[2]. Because EMT is closely related to the proliferation, 
metastasis and prognosis of malignant tumor, it has 
become an important hot spot for pharmacological stud-
ies on tumors [3]. Transforming growth factor (TGF-β) 
is one of the most important signal molecular that can 
initiate the EMT process [4]. During TGF-β-mediated 
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EMT, TGF-β initiates responses by contacting two types 
of transmembrane serine/threonine kinases called recep-
tors type I and type II, promoting activation of the type I 
by the type II kinase. The activated type I receptor then 
propagates the signal to the nucleus by phosphorylating 
Smad2 and Smad3. Once phosphorylated, Smad2 and 
Smad3 associate with the shared partner Smad4 and the 
complexes accumulate in the nucleus where they regulate 
the expression of TGF-β target genes through coopera-
tive interactions with transcriptional partners, which is 
process of the classical Smad-dependent signaling path-
way that TGF-β induced [5, 6]. Many studies showed that 
a variety of Stellera chamaejasme L. extracts or mono-
mers had anti-tumor activities and could induce apop-
tosis of tumor cells [7–10]. Our previous studies also 
got the same results [11, 12], but there were no experi-
ments on its anti-metastasis effects. In this study, we 
further observed the effects of ESC on TGF-β-mediated 
EMT and classical Smad-dependent signaling pathway in 
HepG2 liver cancer cells.
Methods
Cell line and cell culture
HepG2 liver cancer cell lines were preserved in Beijing 
Institute of Hepatology. HepG2 cells were cultured in 
DMEM medium (Gibco, Grand Island, NY, USA) supple-
mented with 10 % fetal bovine serum (China Hangzhou 
Sijiqing Biological Technology Co., Ltd) and maintained 
at 37 °C in a humidified incubator with 5 % CO2.
Reagents and antibodies
Process of ESC (Extract of Stellera Chamaejasme L.) 
and determination of part components of ESC was pro-
vided in another paper [11]. Trypsin-ethylene-diami-
netetraacetic acid (EDTA) and DMEM medium were 
purchased from Gibco (Grand Island, NY, USA);3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bro-
mide (MTT), dimethyl sulfoxide (DMSO) and SB431542 
were provided by Sigma Chemical Co. (St. Louis, MO, 
USA); TGF-β was from R&D Systems (Miniieapolis, MN, 
USA); E-cadherin, Vimentin and β-actin primary mono-
clonal antibody were purchased by Abcam Ltd (Cam-
bridgem MA, USA); Matrigel was from BD Biosciences 
(Los Angeles, CA, USA); Crystal violet was from Beijing 
Solarbio Science and Technology Co., Ltd; Smad and 
p-Smad primary monoclonal antibody were from Cell 
Signal Technology, Inc (Beverly, MA, USA).
MTT assay
Cells in the logarithmic growth phase were plated in 96-well 
plates in a seeding density of 5000 cells/well and incubated 
in a 37  °C incubator with 5  % CO2 overnight. After cells 
were treated with ESC (final concentration was respectively, 
100, 50, 25, 12.5, 6.25, 3.125, 1.562, 0 μg/mL) for 24, 48, 72 h, 
the culture medium in each well was abandoned, incubating 
with 0.5 g/L MTT 100 μL for 4 h. Then each well was added 
with 150 μL DMSO and vibrated for 10 min, and absorb-
ance of each well was detected with microplate reader 
(ELX800 type, BIO-TEX Instruments, INC, Winooski, VT, 
USA) at the 490 nm wavelength. The inhibition rate (IR) was 
calculated as follows: IR (%) = (1 − ODtreatment/ODcontrol) × 
100  %. Then half-maximal inhibitory concentration (IC50) 
was determined by logistic method.
Scattering assay
Cells (2 × 104) were seeded in each well of 24-well plate 
and incubated at 37  °C with 5  % CO2 overnight. Cells 
were pretreated with indicated concentration of ESC for 
the appropriated time and then TGF-β was added to each 
well with the final concentration of 5 ng/mL. Cells were 
incubated at 37  °C with 5 % CO2 for 24 h. Representive 
photographs were taken using an inverted microscope 
(Olympus, Japan).
Wound healing assay
Cells (5 × 105) were plated in a 6-well plate (three lines were 
drawn at the external bottom of each well) and incubated in 
a 37 °C incubator with 5 % CO2 overnight to form a con-
fluent monolayer. The monolayers were scratched vertically 
to the lines by a plastic tip and washed by PBS to remove 
cell debris. Indicated concentrations of ESC and 5 ng/mL 
TGF-β were then added to each well, and the plates were 
incubated at 37 °C incubator with 5 % CO2 for 24 h. Pho-
tographs of wound closure were taken at the intersection 
point of lines and scratches at the point time of 0 and 24 h 
by the inverted microscope and the distance of wound clo-
sure was measured by Photoshop 8.0 software.
Relative closure rate (%)
= 1−
Distance of treatment group at 0 h− Distance of treatment group at 24 h
Distance of control group at 0 h− Distance of control group at 24 h
In vitro invasion assay
The matrigel invasion experiment was analyzed in 
24-well transwell plates.  25 μL matrigel matrix was 
resolved at 4  °C overnight and coated on the transwell 
insert membrane (Corning Incorporated). After the 
inserts were incubated at 37 °C for 30 min, 2 × 104 cells 
in 100 μL of DMEM medium with 1 % BSA and different 
concentrations of ESC were added to the top chamber 
and 500 μL of 10 % serum-containing DMEM and 5 ng/
mL TGF-β were added in the bottom chamber. The cells 
were then incubated at 37 °C with 5 % CO2 for 24 h. After 
incubation, the medium was removed, and non-invading 
cells were scrubbed by a wet cotton swab. The invading 
cells were washed by PBS for three times and fixed by 4 % 
paraformaldehyde for 15  min. Fixed cells were washed 
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three times by PBS and stained by 0.1  % crystal violet 
in PBS for 10 min. Excess stain was washed by distilled 
water for three times. The invading cells were counted in 
five random fields using an inverted microscope.
In vitro migration assay
The methods of migration assay were same to the inva-
sion assay, but the transwell insert membranes were not 
coated by matrigel.
Western blot analysis
Cells were seeded in 100 mm tissue culture dishes at the 
density of 2 ×  106 cells per dish and incubated for over-
night. Cells were then treated with various agents as indi-
cated in figure legends, then washed with ice-cold PBS 
and harvested in 400 μL of cell lysis buffer. The protein 
concentrations of lysates were determined using the bicin-
chonininc acid method. Cell lysates (40 μg per lane) were 
separated using 10 % SDS-PAGE and transferred electro-
phoretically to polyvinylidenedifluoride membrane. Mem-
branes were blocked with tris-buffered saline/0.1 % tween 
20 containing 5 % bovine serum albumin and then incu-
bated overnight at 4 °C with primary antibodies (1:1000). 
Membranes were washed three times with TBST and 
incubated for 1  h at room temperature with the appro-
priate secondary antibody conjugated to goat anti-rabbit 
horseradish peroxidase (1:2000). Membranes were then 
washed and immunoreactive band were developed with 
ECL and visualized by autoradiography. Protein loading 
was normalized using β-actin antibody. Gray-scale analysis 
of protein bands was performed using image software.
Immunofluorescence analysis
Cells were seeded into 24-well plates and treated as 
described above. Cells were fixed with 4 % formaldehyde for 
30 min, washed with PBS, blocked with 5 % BSA for 30 min 
at room temperature, and then stained with anti-human 
primary antibody (1:100) at 4 °C overnight. Cells were incu-
bated with anti-rabbit-FITC secondary antibody (1:500) 
for 2 h at 4 °C, and then washed with PBS. Cells were then 
incubated for 10  min at room temperature with DAPI to 
stain nuclei, washed twice with PBS, and observed using an 
inverted fluorescence microscope (Olympus, Japan).
Statistical analysis
All the data were expressed as the mean  ±  SD. The 
results were subjected to the one way ANOVA test using 
SPSS software (17.0 version).
Results
TGF‑β induced EMT in HepG2 cells
First, the optimal concentrations of TGF-β to initiate the 
EMT in HepG2 cells were determined. Changes of cell 
morphology were observed after treatment with various 
concentrations (0.1–10 ng/mL) of TGF-β for 24 h. HepG2 
cells were subjected to morphological changes under 
exposure to various concentrations of TGF-β. HepG2 
cells showed a classical cobblestone epithelial morphology 
in the absence of TGF-β, but after stimulation with vari-
ous concentrations of TGF-β for 24  h, the cells showed 
a fibroblast-like morphology and cell–cell adhesion also 
reduced (Fig. 1a). The expressions of epithelial phenotype 
marker, E-cadherin, and mesenchymal phenotype marker, 
Vimentin, were also determined after treatment with 
various concentration of TGF-β for 24 h in HepG2 cells. 
TGF-β decreased the E-cadherin and induced the Vimen-
tin expression in HepG2 cells (Fig.  1b, c). These results 
suggested that TGF-β could induce EMT in HepG2 cells.
The cytotoxic effect of ESC on HepG2 cells
The dosage of ESC for EMT experiments must be deter-
mined to avoid the influence of anti-proliferation of ESC. 
Cytotoxicity of ESC was evaluated in HepG2 cells using 
MTT assay. Doses of ESC up to 12.5 μg/mL (0, 1.56, 3.13, 
6.25) exhibited no significant inhibition on HepG2 cells, 
whereas higher doses of ESC (>12.5 μg/mL) significantly 
inhibited HepG2 cell viability in HepG2 cells (Fig.  2). 
IC50 of ESC on HepG2 cells for 24, 48, 72 h were respec-
tively, 85.99, 59.75 and 54.57 μg/mL. Therefore, the doses 
less than 12.5  μg/mL were chosen for following EMT 
experiments.
ESC reversed cell scattering induced by TGF‑β in HepG2 
cells
The TGF-β induced EMT was characterized by cell scat-
tering (Fig.  1). To make out whether ESC could influ-
ence TGF-β-induced cell scattering, HepG2 cells were 
stimulated with TGF-β (5  ng/mL) before treated with 
ESC. In order to eliminate the interference of prolifera-
tion inhibition of ESC on its block-scattering, we chose 
low toxicity concentrations (<12.5 μg/mL) of ESC for the 
further experiments. HepG2 cells were pretreated with 
various concentrations of ESC (1–5 μg/mL) for 2 h before 
stimulated with TGF-β for 24 h. The results showed that 
5 and 1 μg/mL ESC blocked this scattering significantly 
(Fig. 3A). We pretreated HepG2 cells with 5 μg/mL ESC 
for varying periods from 2 to 6 h before TGF-β addition 
and time-dependent reversing effect of ESC was showed 
(Fig. 3B). These results showed that ESC could inhibit the 
cell scattering induced by TGF-β in HepG2 cells.
ESC reversed EMT induced by TGF‑β in HepG2 cells 
by down‑regulation of Vimentin and up‑regulation 
of E‑cadherin
Pretreated with ESC (0.2–5  μg/mL) for 2  h in HepG2 
cells significantly inhibited up-regulation of Vimentin 
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Fig. 1 TGF‑β induced EMT in HepG2 cells. a Changes of cell morphology were assessed following treatment of HepG2 cells with various concen‑
trations (0.1–10 ng/mL) of TGF‑β for 24 h. The magnification is 100 times. b The expressions of E‑cadherin and Vimentin were determined with 
immunofluorescence method in HepG2 cells treated with TGF‑β (5 ng/mL) for 24 h. The magnification is ×400. c The expressions of E‑cadherin, and 
Vimentin were measured with western blot analysis in HepG2 cells treated with various concentrations (0.1–10 ng/mL) TGF‑β for 24 h
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and down-regulation of E-cadherin induced by 5 ng/mL 
TGF-β for 24 h (Fig. 4a, b). HepG2 cells were pretreated 
with 5  μg/mL ESC for different hours (1–4  h) prior to 
5 ng/mL TGF-β stimulation, the time-dependent effects 
of ESC were showed (Fig.  4c). These results suggested 
that ESC reversed marker proteins changes of EMT 
induced by TGF-β in HepG2 cells.
ESC inhibited the TGF‑β‑induced cell migration 
and invasion
We also further examined whether ESC affected TGF-
β-induced cell migration and invasion. Our results 
showed that TGF-β significantly induced cell migra-
tion and ESC (0.2–5  μg/mL) could notably block this 
migration (Fig.  5a). The same results were observed 
with transwell assay and the results were not showed. 
A modified invasion assay with transwell method was 
also performed to further determine whether ESC 
blocked TGF-β-induced invasion. ESC (0.2–5  μg/mL) 
obviously decreased the number of TGF-β induced 
invasive cells (Fig.  5b). These results suggested that 
ESC inhibited the TGF-β-induced cell migration and 
invasion in HepG2.
ESC inhibited TGF‑β‑initiated Smad signaling pathway
Since TGF-β could induce the Smad2 phosphorylation, we 
tried to figure out whether ESC could inhibit this initiation. 
We found that 5 ng/mL of TGF-β induced Smad2 phospho-
rylation within 0.5–6 h, and the level of Smad2 phospho-
rylation reached a maximum between 30 and 60 min after 
treatment but total Smad2 expression was not be affected 
during the whole stimulation period. Pretreatment with 
5 μg/mL ESC for 0.5–6 h significantly inhibited the expres-
sion of phosphorylation of Smad2 induced by TGF-β, but 
no influence on the whole smad2 expression (Fig. 6a). Our 
results found that 5  ng/mL TGF-β could induce Smad2 
nucleus translocation and pretreatment of ESC (5 μg/mL) 
for 2 h could reverse this nucleus translocation in hepG2 
cells (Fig.  6b). These results suggested that ESC could 
inhibit TGF-β-induced Smad2 phosphorylation and Smad2 
Nuclear import. The western blot analysis revealed that 
TGF-β induced smad2 phosphorylation, down-regulated 
the E-cadherin and up-regulated the Vimentin. SB431542 
(25  μM) could reverse these effects of TGF-β in HepG2 
cells. The ESC (5  μg/mL) also could inhibit Smad2 phos-
phorylation, up-regulate E-cadherin and down-regulate 
Vimentin induced by TGF-β. The reversing effects of copre-
treatment with ESC (5 μg/mL) and SB432542 (25 μM) on 
phosphorylation of smad2 and Vimentin were more potent 
than pretreatment with SB431542 or ESC alone (Fig.  6c). 
Cell migration and invasion were significantly inhibited by 
treatment with SB431542 and ESC, copretreatment with 
ESC and SB432542 showed more potent inhibition on cell 
migration and invasion induced by TGF-β than treatment 
with SB431542 or ESC alone (Fig.  6d). These results sug-
gested that ESC could reversing EMT induced by TGF-β 
and this reversing effect might be related to its inhibition of 
Smad signaling pathway.
Discussion
Hepatocellular carcinoma is an extreme malignant tumor, 
and early metastasis is one of the important reasons for 
its poor prognosis. EMT is an important step in the inva-
sion and metastasis of many cancers, and TGF-β induces 
progression of cancer through EMT [13, 14]. Many 
researches confirmed that high expression or activation 
of TGF-β in metastatic tumors [15, 16]. So, as a classic 
model of EMT induced by TGF-β, it was widely used 
and we made this model in HepG2 cells to mimic the 
metastasis in vitro. Our experiment results showed that 
HepG2 cells were sensitive to the different concentration 
of TGF-β (0.1–10  ng/mL) and TGF-β not only changed 
the morphology but also the molecular markers of the 
HepG2 cells. HepG2 cells induced by TGF-β appeared 
the fibroblast-like morphology, with down-regulation 
of the E-cadherin and up-regulation of Vimentin, which 
Fig. 2 The inhibitory effect of ESC on HepG2 cells. The OD values of HepG2 cells treated with various concentrations ESC (0–100 μg/mL) were 
determined using MTT assay (*p < 0.05 vs control group)
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was consistent with other reports [17]. These results sug-
gested that TGF-β could induce EMT in HepG2 cells.
ESC, the extract of Stellera Chamaejasme L., inhibited 
proliferation and induced apoptosis in various tumor cells 
by activation apoptotic death receptor signaling pathway in 
our previous researches [11, 12]. In this study, we found that 
EMT induced by TGF-β in HepG2 cells could be reversed 
by ESC (doses less than 12.5 μg/mL were used to avoid the 
influence of anti-proliferation of ESC). The results showed 
ESC (1–10 μg/mL) could reverse the cell scattering induced 
by TGF-β and this effect appeared time-dependent style. To 
further clarify whether ESC inhibition of TGF-β-induced 
scattering in HepG2 cells resulted from dysregulation of 
EMT related proteins, influence of ESC on E-cadherin and 
Vimentin expression was observed. E-cadherin (epithelial 
marker protein) is a well-studied member of the cadherin 
family. In epithelial cells, E-cadherin-containing cell-to-
cell junctions are often adjacent to actin-containing fila-
ments of the cytoskeleton [18]. Loss of E-cadherin function 
or expression has been implicated in cancer progression 
and metastasis. E-cadherin downregulation decreases the 
strength of cellular adhesion within a tissue, resulting in 
an increase in cellular motility [19]. Vimentin is a type III 
intermediate filament (IF) protein that is expressed in mes-
enchymal cells. Vimentin is the major cytoskeletal com-
ponent of mesenchymal cells. Because of this, Vimentin is 
often used as a marker of mesenchymally-derived cells or 
cells undergoing an epithelial mesenchymal transition dur-
ing both normal development and metastatic progression 
[20, 21]. We examined the expressions of these two marker 
proteins in HepG2 cells with immunofluorescence and 
western blot assay. ESC (0.2–5  μg/mL) could reverse the 
Fig. 3 ESC reversed cell scattering induced by TGF‑β in HepG2 cells. A Different concentration ESC (1–5 μg/mL) on cell scattering induced by TGF‑β 
for 24 h. The magnification is ×200. B HepG2 cells treated with 5 μg/mL ESC for varying periods (2–6 h) prior to TGF‑β addition. Vehicle (medium 
containing 0.2 % DMSO) was used to be as parallel control. The magnification is ×200. Note: c in this figure and other figures means vehicle control
(see figure on next page) 
Fig. 4 ESC reversed EMT induced by TGF‑β in HepG2 cells by down‑regulation of Vimentin and up‑regulation of E‑cadherin. a Expressions of 
Vimentin and E‑cadherin in HepG2 cells pretreated with different concentrations (1–5 μg/mL) of ESC prior 2 h to TGF‑β (5 ng/mL) incubation for 
24 h with immune‑fluorescence assay. The magnification is ×400. b Western blot results of Vimentin and E‑cadherin in HepG2 cells pretreated with 
different concentrations (0.2–5 μg/mL) of ESC prior 2 h to TGF‑β (5 ng/mL) incubation for 24 h. c Western blot results of Vimentin and E‑cadherin in 
HepG2 cells pretreated with 5 μg/mL ESC for different hours (1–4 h) prior to 5 ng/mL TGF‑β stimulation. Western blot data presented were repre‑
sentative of those obtained in at least 3 separate experiments. The value of the control cells was set to 1
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changes of two marker proteins in hepG2 cells induced by 
TGF-β which dedicated that ESC could decrease cellular 
motility and metastasis. The results of wound closure and 
transwell assay further confirmed this inhibition effect of 
ESC in migration and invasion induced by TGF-β. These 
data suggested that ESC could restrain the EMT mediated 
by TGF-β.
How does the ESC reverse TGF-β-induced EMT in 
hepG2 cells? Smad-dependent signaling was classi-
cal pathway mediated by TGF-β. TGF-β superfamily 
ligands bind to a type II receptor, which recruits and 
phosphorylates a type I receptor. The type I receptor 
then phosphorylates receptor-regulated Smad2/3 which 
can bind the Smad4. P-Smads/Smad4 complexes accu-
mulate in the nucleus where they act as transcription 
factors and participate in the regulation of EMT target 
gene expression [22, 23]. Under resting state, Smad2 is 
unphosphorylated and retain in the cytoplasma. Upon 
activation of TGF-β, Smad2 is phosphorylated and 
undergoes dimerization with Smad3, thus permitting its 
translocation into nucleus [24]. Our results showed that 
ESC could inhibit the up-regulation of p-Smad2 but did 
not influence the expression of Smad2. The subcellular 
location results showed that ESC could inhibit the Smad2 
nuclear translocation. These results suggested that ESC 
really could reverse TGF-β induced EMT by regulating 
Smad signal pathway.
In Smad signal pathway, which was the key regulat-
ing point of ESC in reversing EMT induced by TGF-β in 
hepG2 cells? We use a specific inhibitor of TβRI kinases, 
SB432542 [25] to inhibit TGF-β-induced phosphoryla-
tion of Smad2 [25]. We found that blocking the function 
of TβRI kinases with SB432542 resulted in inhibition of 
Smad2 phosphorylation, up-regulation of E-cadherin, 
down-regulation of Vimentin, with the decreasing activi-
ties of migration and invasion in hepG2 cells induced by 
TGF-β. ESC not only had same effects to SB432542, but 
also enhanced these effects of SB432542. These results 
Fig. 5 Effects of ESC on TGF‑β‑induced cell migration and invasion. a Effect of ESC on TGF‑β induced cell migration with wound healing assay. ESC 
(0.2–5 μg/mL) significantly inhibited TGF‑β induced cell motility (*p < 0.05 vs control group).The magnification is 40 times. b Effect of ESC (0.2–5 μg/
mL) on TGF‑β induced cell invasion with transwell assay. ESC (0.2–5 μg/mL) significantly inhibited TGF‑β‑induced cell invasion (*p < 0.05 vs control 
group). The magnification is ×100
(see figure on next page) 
Fig. 6 ESC inhibited TGF‑β‑induced Smad signaling pathway. a Pretreatment with 5 μg/mL ESC for 2 h significantly suppressed the expression of 
phosphorylation of Smad2 induced by TGF‑β for 0.5–6 h, but no influence on expression of Smad2. b Pretreatment of 5 μg/mL ESC for 2 h could 
inhibit the nucleus translocation induced by TGF‑β in hepG2 cells. The magnification is 200 times. c 5 μg/mL ESC and 25 μM SB432542 significantly 
reversed EMT proteins induced by TGF‑β, inhibiting expression of phosphorylation of Smad2 and Vimentin, enhancing expression of E‑cadherin and 
the coordination of ESC and SB432542 was showed. d 5 μg/mL ESC and 25 μM SB432542 could inhibited cell migration and invasion induced by 
TGF‑β and also showed coordination effects
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suggested that ESC might be a potential inhibitor of TβRI 
kinases which might be the key regulating point of ESC 
in reversing EMT induced by TGF-β in hepG2 cells.
In summary, our observations showed that ESC could 
reverse the EMT mediated by TGF-β in hepG2 liver cells 
via inhibition of Smad signaling pathway. ESC may have 
good prospects in the prevention and treatment of hepa-
tocellular carcinoma metastasis.
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